- Home
- WCT vs XFOR Comparison
WCT vs XFOR Comparison
Compare WCT & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WCT
- XFOR
- Stock Information
- Founded
- WCT 2012
- XFOR 2014
- Country
- WCT Hong Kong
- XFOR United States
- Employees
- WCT N/A
- XFOR N/A
- Industry
- WCT
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WCT
- XFOR Health Care
- Exchange
- WCT NYSE
- XFOR Nasdaq
- Market Cap
- WCT 100.9M
- XFOR 118.4M
- IPO Year
- WCT 2024
- XFOR N/A
- Fundamental
- Price
- WCT $2.42
- XFOR $0.47
- Analyst Decision
- WCT
- XFOR Strong Buy
- Analyst Count
- WCT 0
- XFOR 3
- Target Price
- WCT N/A
- XFOR $3.50
- AVG Volume (30 Days)
- WCT 3.7M
- XFOR 6.8M
- Earning Date
- WCT 12-07-2024
- XFOR 03-20-2025
- Dividend Yield
- WCT N/A
- XFOR N/A
- EPS Growth
- WCT N/A
- XFOR N/A
- EPS
- WCT 0.05
- XFOR N/A
- Revenue
- WCT $2,370,163.00
- XFOR $1,123,000.00
- Revenue This Year
- WCT N/A
- XFOR N/A
- Revenue Next Year
- WCT N/A
- XFOR $590.67
- P/E Ratio
- WCT $52.43
- XFOR N/A
- Revenue Growth
- WCT N/A
- XFOR N/A
- 52 Week Low
- WCT $0.94
- XFOR $0.26
- 52 Week High
- WCT $9.36
- XFOR $1.60
- Technical
- Relative Strength Index (RSI)
- WCT N/A
- XFOR 41.75
- Support Level
- WCT N/A
- XFOR $0.46
- Resistance Level
- WCT N/A
- XFOR $0.54
- Average True Range (ATR)
- WCT 0.00
- XFOR 0.05
- MACD
- WCT 0.00
- XFOR -0.01
- Stochastic Oscillator
- WCT 0.00
- XFOR 5.63
About WCT WELLCHANGE HOLDINGS COMPANY LIMITED
Wellchange Holdings Co Ltd is an enterprise software solution services provider. It provides software solutions, cloud-based software-as-a-service (SaaS) platforms, and white-label software design and development services.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.